The stock of niche financial software company Vertex (NASDAQ: VERX) didn't get a very good start to the trading week at all.

VRTX tops Q3 earnings and revenue estimates on strong Trikafta and Alyftrek sales, but shares slip as Casgevy sales disappoint.

Vertex (NASDAQ: VERX) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table below ...

The stock's fall snapped a three-day winning streak.

Vertex (VERX) remains unprofitable but is narrowing its losses at an average rate of 16.4% per year over the past five years. Looking ahead, the company’s annual revenue is expected to grow by 12.4% ...

Fintel reports that on November 4, 2025, Citizens maintained coverage of Vertex (NasdaqGM:VERX) with a Market Outperform ...

For the quarter ended September 30, Vertex Pharmaceuticals reported adjusted earnings of $4.80 per share, marking an increase from $4.38 in the same quarter last year. This positive performance not ...

Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities ...

It is a smart strategy to diversify your portfolio by investing in high-quality companies built on proven technologies.

Baystreet.ca News Commentary – The global biologics industry is experiencing unprecedented expansion as the market surges ...

The post Market Analysis: Nov 4th, 2025 appeared first on Stock Target Advisor.

Detailed price information for Teladoc Health Inc (TDOC-N) from The Globe and Mail including charting and trades.